Slow-Release 5-Amino-Salicylic Acid (Pentasa®) for the Treatment of Active Crohn’s Disease
Authors:
- D.P. JewellDJD.P. Jewell
- 1 January 1990
- journal article
- research article
- Published by S. Karger AG in Digestion
- Vol. 45 (2) , 88-92
Abstract
A double-blind, placebo-controlled trial of a slow-release preparation of 5-amino-salicylic acid (Pentasa) has been performed in 40 patients with active Crohn's disease. Over a 6-week period, Pentasa (1.5 g daily) was no different to the dummy tablet in terms of clinical activity (Harvey-Bradshaw Index) or laboratory indicators of inflammation. No serious adverse reactions occurred.Keywords
This publication has 2 references indexed in Scilit:
- Therapeutic Efficacy of Sulfasalazine and Its Metabolites in Patients with Ulcerative Colitis and Crohn's DiseaseNew England Journal of Medicine, 1980
- National Cooperative Crohn's Disease Study: Results of drug treatmentGastroenterology, 1979